Morning All!
Not a huge amount to cover this morning.
Closure Of Grain D’Or And Trading Update For The Year To End June 2018 – Closure of a loss making factory (for the financial year to end June 2017 it reported an operating loss of £3.33 million on revenues of £28.5 million). Costs could be up to £10m spread over 7 years, but likely to be in the region of £6m. The Company will benefit from the cancellation of planned capital investment programmes in Grain D'Or, which were significant.
The Board's expectations for the year to end June 2018 remain consistent with the guidance previously delivered to the market, albeit that the adjusted profit performance will be achieved from a lower revenue base.
Seems like a positive move but I just get a bit of a calm before the storm feeling here – For some strange reason. Not something I would be investing in at present.
Trading Update For The Year To End September 2017 – Results expected to be marginally ahead of the Boards expectations. Group Revenue for the year up 8.9% and also considering (due to strong cash generation) a return of capital to shareholders. Tempted a little here, but on a PER of 15 it’s probably about fair value here. A correction to the 160p level (which has happened a number of times in the past) will be more tempting.
Trading Update For The 6 Months To End September 2018 – Positive stuff here. Expecting Revenue growth of 18% LFL. Two new sites (one year old) are both delivering an encouraging performance – New Sheffield site, opened in April is building good sales momentum. This also looks like good news…
On a PER of 8.13 - If there’s interest in the sector out there, this update should provide a tailwind here (for those not worried about the HUGE Net Debt).
Trading Update For The Year To End September 2017 – The headline is “An outstanding year, strengthening our leading position in Life Sciences”. Revenues expected to be £163m vs £122m (33%+). Adjusted PBT is also expected to be ahead of market expectations. The group has benefitted from…
